Delveinsight Report

  Trastuzumab Biosimilars Market Overview Trastuzumab is a humanized IgG1 kappa monoclonal antibody designed to target the HER2 receptor and is widely used for HER2-positive breast cancer as well as selected gastric and gastroesophageal junction cancers. Herceptin, the reference biologic, established trastuzumab as an important targeted oncology treatment. The expanding trastuzumab biosimilars landscape is introducing additional biologic alternatives and increasing competition within the global oncology market. DelveInsight's analysis evaluates more than 35 companies and over 35 marketed and pipeline products involved in this therapeutic segment. Trastuzumab Biosimilars and HER2-Targeted Treatment Trastuzumab works by selectively binding with high affinity to the extracellular domain of HER2, a receptor that plays a significant role in tumor cell growth and progression. The biologic is manufactured using recombinant DNA technology in mammalian cell culture systems. The reference p...

  Tissue Heart Valves Market Overview The global Tissue Heart Valves Market is witnessing strong growth as the prevalence of valvular heart disorders rises and healthcare providers increasingly adopt advanced replacement technologies. According to DelveInsight, the market was valued at USD 10,743.75 million in 2025 and is anticipated to reach USD 25,307.93 million by 2034, expanding at a CAGR of 10.08% during 2026–2034. The heart valves market is benefiting from the growing incidence of aortic stenosis and mitral regurgitation, an aging population, and the increasing utilization of minimally invasive valve replacement procedures. Tissue Heart Valves Market Driven by Valvular Disease Prevalence The rising global burden of valvular heart disease is a major factor contributing to expansion of the Tissue Heart Valves Market. Aortic stenosis represents a significant indication for valve replacement, particularly among elderly individuals. DelveInsight estimates that approximately 10% o...